# Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection

> **NCT05752175** · PHASE2 · COMPLETED · sponsor: **Westlake Pharmaceuticals (Hangzhou) Co., Ltd.** · enrollment: 80 (actual)

## Conditions studied

- COVID-19 Infection

## Interventions

- **DRUG:** WPV01
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT05752175
- **Lead sponsor:** Westlake Pharmaceuticals (Hangzhou) Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2023-03-10
- **Primary completion:** 2023-05-09
- **Final completion:** 2023-07-03
- **Target enrollment:** 80 (ACTUAL)
- **Last updated:** 2024-06-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05752175

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05752175, "Study of WPV01 Compared With Placebo in Patients With Mild/Moderate COVID-19 Infection". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT05752175. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*